EDG-5506-201
Recruiting
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a multicenter, randomized, Phase 2, double-blind, placebo-controlled study to evaluate the effect of EDG-5506 on the safety, PK, biomarkers, and functional measures in adult and adolescent participants with BMD. This randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics (PK), and efficacy of EDG-5506 in adults and adolescents with genetically confirmed BMD.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
03 Sep 2024.
Study ID: 853514
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting